Effector and central memory T helper 2 cells respond differently to peptide immunotherapy

摘要: Peptide immunotherapy (PIT) offers realistic prospects for the treatment of allergic diseases, including asthma. Much is understood behavior naive T cells in response to PIT. However, patients with ongoing disease requires detailed understanding responses allergen-experienced cells. CD62L expression by corresponds effector/effector memory (CD62Llo) and central (CD62Lhi) subsets, which vary allergen exposure (e.g., during, or out with, pollen season). The efficacy PIT on different helper 2 (Th2) cell populations unknown. We developed a murine model airway inflammation (AAI) driven adoptively transferred, traceable ovalbumin-experienced Th2 effectively suppressed AAI unfractionated Selective transfer CD62Lhi CD62Llo revealed that these two behaved differently from one another previously characterized (early deletional) CD4+ Most notably, allergen-reactive were long-lived within lung after PIT, before challenge, contrast Despite this, was most potent against protecting AAI, impairing their ability produce cytokines, whereas this capacity heightened PIT-treated conclude do not undergo an early deletional form tolerance Moreover, subsets respond These findings have implications clinical translation scenarios.